ASCO 2023 | A phase I/II trial to preliminary efficacy of BNT142 in prospectively confirmed CLDN6+ solid tumors

Timothy Yap, MBBS, PhD, FRCP, The University of Texas MD Anderson Cancer Center, Houston, TX, provides an overview of a Phase I/II clinical trial (NCT05262530) to evaluate the safety and efficacy of BNT142, a novel RNA-encoded antibody targeting Claudin 6 (CLDN6), in patients with advanced solid tumors expressing CLDN6. CLDN6 is found in various cancers, including testicular, ovarian, endometrial, and non-squamous non-small-cell lung cancer. BNT142, consisting of lipid nanoparticle-encapsulated RNAs, encodes a T-cell-engaging bispecific antibody against CLDN6 and CD3. The study aims to determine the recommended Phase II dose (RP2D) through dose escalation and expansion cohorts. Patients who have exhausted standard therapies or are not suitable candidates for available treatments are eligible. This trial explores the potential of RNA-encoded antibodies as a rapid and effective immunotherapy strategy for CLDN6+ advanced solid tumors. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.